NextCure, Inc. — Form 10-Q

NextCure and LigaChem Biosciences executed a Transition and Continuation Agreement effective August 6, 2026, under which LigaChem assumes sole development and 100% funding of the LNCB74/B7-H4 ADC program (previously 50/50 co-funded). NextCure transfers ADC patent prosecution rights and reversion technology to LigaChem, retains antibody patent prosecution, and receives milestone and royalty payments (reduced by redacted %) from exhibit B of original agreement, plus FTE support reimbursement capped at redacted amount through redacted date. Simultaneously, NextCure terminated ~39,432 sq ft of leased space (Suites 180, 200, 201 at two Maryland locations) effective July 31, 2026, paying landlord $760,000 termination fee, reducing total premises from ~63,576 to ~29,864 sq ft, with tenant's operating expense share reduced from redacted to 76.25%.